CFC phase-out by therapeutic class is inappropriate, Glaxo's Rickard tells advisory committee.
CFC PHASE-OUT BY THERAPEUTIC CLASS IS INAPPROPRIATE, GLAXO WELLCOME U.S. Medical Affairs Respiratory Director Kathleen Rickard, MD, said at an April 11 FDA Pulmonary-Allergy Drugs Advisory Committee meeting on FDA's proposed chloro-fluorocarbons phase-out process. "The continued availability of individual class products should be a major consideration in light of the proposal that could reduce available medications to two active ingredients per therapeutic class," Rickard said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth